Evidence map›Paper›PMID 31943834›Full record

Trial reportCancer medicine2020

A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck.

Tomohiro Enokida, Takenori Ogawa, Akihiro Homma, Kenji Okami, Shujiro Minami, Ayako Nakanome, Yasushi Shimizu, Daisuke Maki, Yuri Ueda, Takao Fujisawa and 7 more

Abstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Tomohiro EnokidaDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, Chiba, Japan.ORCID 0000-0001-6505-7591
Takenori OgawaDepartment of Otolaryngology - Head and Neck Surgery, Tohoku University School of Medicine, Miyagi, Japan.
Akihiro HommaDepartment of Otolaryngology, Head & Neck Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Kenji OkamiDepartment of Otolaryngology - Head Neck Surgery, Tokai University, Kanagawa, Japan.
Shujiro MinamiDepartment of Otorhinolaryngology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
Ayako NakanomeDepartment of Otolaryngology - Head and Neck Surgery, Tohoku University School of Medicine, Miyagi, Japan.
Yasushi ShimizuDepartment of Medical Oncology, Hokkaido University Hospital, Sapporo, Japan.
Daisuke MakiDepartment of Otolaryngology - Head Neck Surgery, Tokai University, Kanagawa, Japan.
Yuri UedaDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, Chiba, Japan.
Takao FujisawaDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, Chiba, Japan.
Atsushi MotegiDivision of Radiation Oncology and Particle Therapy, National Cancer Center Hospital East, Chiba, Japan.
Akira OhkoshiDepartment of Otolaryngology - Head and Neck Surgery, Tohoku University School of Medicine, Miyagi, Japan.
Jun TaguchiDepartment of Medical Oncology, Hokkaido University Hospital, Sapporo, Japan.
Koji EbisumotoDepartment of Otolaryngology - Head Neck Surgery, Tokai University, Kanagawa, Japan.
Shogo NomuraBiostatistics Division, Center for Research Administration and Support, National Cancer Center, Chiba, Japan.
Susumu OkanoDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, Chiba, Japan.
Makoto TaharaDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, Chiba, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInduction chemotherapy (IC) in locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) often compromises compliance with subsequent chemoradiotherapy (CRT), which negatively affects outcomes. Here, we assessed the combination of paclitaxel (PTX), carboplatin (CBDCA), and cetuximab (Cmab) as IC for unresectable LA-SCCHN.

methodsInduction chemotherapy consisted of weekly CBDCA area under the plasma concentration-time curve = 1.5, PTX 80 mg/m

resultsThirty-five patients were enrolled. Cases were hypopharynx/oropharynx/larynx in 17/17/1 patients, all at Stage IV. Of 35 patients, 34 (97%) completed IC and 32 received CRT and met the criteria of full analysis set (FAS). In FAS, the %CRT completion was 96.9%, and PP was 99.9%, exceeding the prespecified boundary of 84%. Mean cumulative dose and relative to dose intensity of CDDP in CRT was 232.5 mg/m

conclusionsPCE as IC was feasible, with promising efficacy and no effect on compliance with subsequent CRT in unresectable LA-SCCHN.

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCetuximabChemoradiotherapyDrug EruptionsFeasibility StudiesFemaleHead and Neck NeoplasmsHumansInduction ChemotherapyMaleMiddle AgedMucositisNeutropeniaCarboplatinCetuximabPaclitaxelcarboplatincetuximabchemoradiotherapyinduction chemotherapypaclitaxelunresectable locally advanced squamous cell carcinoma of the head and neck

Identifiers

PMID31943834
PMCPMC7050099

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.